<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">37493802</PMID><DateCompleted><Year>2023</Year><Month>09</Month><Day>21</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1432-1459</ISSN><JournalIssue CitedMedium="Internet"><Volume>270</Volume><Issue>10</Issue><PubDate><Year>2023</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Journal of neurology</Title><ISOAbbreviation>J Neurol</ISOAbbreviation></Journal><ArticleTitle>Longitudinal analysis and treatment of neuropsychiatric symptoms in post-acute sequelae of COVID-19.</ArticleTitle><Pagination><StartPage>4661</StartPage><EndPage>4672</EndPage><MedlinePgn>4661-4672</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00415-023-11885-x</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Persistent neuropsychiatric symptoms following acute COVID-19 infection are frequently reported. These include anxiety, depression, difficulty concentrating, fatigue, and insomnia. The longitudinal evolution of this neuropsychiatric burden is poorly understood and clinical guidelines concerning treatment are lacking.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">We sought to describe the longitudinal evolution of neuropsychiatric symptoms in the post-acute sequelae of COVID-19 (PASC) syndrome and examine symptom treatment at a single center.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Consecutive participants experiencing persistent neurologic symptoms after acute COVID-19 infection were recruited from October 2020 to July 2022. Data collected included COVID-19 infection history, neurological exam and review of systems, Montreal Cognitive Assessment (MoCA), and self-reported surveys concerning neuropsychiatric symptoms and treatment. Data were collected at baseline and at 1-year follow-up.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 106 participants (mean age 48.6, females 67%) were included in the study. At 1-year follow-up, 72.5% of participants reported at least one neuropsychiatric symptom. Over half (52.5%) of participants reported persistent fatigue. At baseline, 38.8% of all participants had met the established MoCA cut-off score of&#x2009;&lt;&#x2009;26 for mild cognitive impairment; this decreased to 20.0% at 1&#xa0;year. COVID-19 infection severity was associated with neuro-PASC symptoms (including fatigue and anxiety) at 1&#xa0;year. Overall, 29% of participants started at least one new medication for COVID-19-associated neuropsychiatric symptoms. Of the participants who started new medications, fatigue was the most common indication (44.8%) followed by insomnia (27.6%).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Neuropsychiatric symptoms related to neuro-PASC improve over time but can persist for over a year post-recovery. Most treatment modalities targeted neuro-PASC fatigue.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Emilie N</ForeName><Initials>EN</Initials><Identifier Source="ORCID">0000-0002-0005-0425</Identifier><AffiliationInfo><Affiliation>Department of Neurosciences, University of California, San Diego, USA. enliu@health.ucsd.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Jennifer H</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, University of California, San Diego, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Rady Children's Hospital San Diego, San Diego, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patel</LastName><ForeName>Lucas</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, University of California, San Diego, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arora</LastName><ForeName>Jasmine</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, University of California, San Diego, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gooding</LastName><ForeName>Amanda</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of California, San Diego, San Diego, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ellis</LastName><ForeName>Ronald</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurosciences and Psychiatry, University of California, San Diego, San Diego, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Graves</LastName><ForeName>Jennifer S</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, University of California, San Diego, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Rady Children's Hospital San Diego, San Diego, CA, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 MH062512</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>07</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>J Neurol</MedlineTA><NlmUniqueID>0423161</NlmUniqueID><ISSNLinking>0340-5354</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001007" MajorTopicYN="N">Anxiety</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005221" MajorTopicYN="N">Fatigue</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007319" MajorTopicYN="Y">Sleep Initiation and Maintenance Disorders</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Long COVID</Keyword><Keyword MajorTopicYN="N">PASC</Keyword><Keyword MajorTopicYN="N">Post-COVID syndrome</Keyword></KeywordList><CoiStatement><b>Conflicts of interest</b> Emilie Liu, Jennifer Yang, Lucas Patel, Jasmine Arora, Amanda Gooding, and Ronald Ellis report no disclosures relevant to the manuscript. Unrelated to the current work, Jennifer Graves has received grant or clinical trial funding from the NMSS, UCSD, Octave, Biogen, EMD-Serono and ABM. She serves on a steering committee for a clinical trial with Novartis and served on advisory boards for TG therapeutics, Genentech and Bayer.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>5</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>7</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>7</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>9</Month><Day>21</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>7</Month><Day>26</Day><Hour>13</Hour><Minute>7</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>7</Month><Day>26</Day><Hour>11</Hour><Minute>12</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>3</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37493802</ArticleId><ArticleId IdType="mid">NIHMS1963161</ArticleId><ArticleId IdType="pmc">PMC10910663</ArticleId><ArticleId IdType="doi">10.1007/s00415-023-11885-x</ArticleId><ArticleId IdType="pii">10.1007/s00415-023-11885-x</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Levine RL (2022) Addressing the long-term effects of COVID-19. JAMA 328:823&#x2013;824. 10.1001/jama.2022.14089</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2022.14089</ArticleId><ArticleId IdType="pubmed">35921084</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng J, Zhou F, Hou W et al. (2021) The prevalence of depression, anxiety, and sleep disturbances in COVID-19 patients: a meta-analysis. Ann N Y Acad Sci 1486:90&#x2013;111. 10.1111/nyas.14506</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nyas.14506</ArticleId><ArticleId IdType="pmc">PMC7675607</ArticleId><ArticleId IdType="pubmed">33009668</ArticleId></ArticleIdList></Reference><Reference><Citation>Taquet M, Geddes JR, Husain M et al. (2021) 6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records. Lancet Psychiatry 8:416&#x2013;427. 10.1016/S2215-0366(21)00084-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2215-0366(21)00084-5</ArticleId><ArticleId IdType="pmc">PMC8023694</ArticleId><ArticleId IdType="pubmed">33836148</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazza MG, De Lorenzo R, Conte C et al. (2020) Anxiety and depression in COVID-19 survivors: role of inflammatory and clinical predictors. Brain Behav Immun 89:594&#x2013;600. 10.1016/j.bbi.2020.07.037</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2020.07.037</ArticleId><ArticleId IdType="pmc">PMC7390748</ArticleId><ArticleId IdType="pubmed">32738287</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudre CH, Murray B, Varsavsky T et al. (2021) Attributes and predictors of long COVID. Nat Med 27:626&#x2013;631. 10.1038/s41591-021-01292-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01292-y</ArticleId><ArticleId IdType="pmc">PMC7611399</ArticleId><ArticleId IdType="pubmed">33692530</ArticleId></ArticleIdList></Reference><Reference><Citation>Shanley JE, Valenciano AF, Timmons G et al. (2022) Longitudinal evaluation of neurologic-post acute sequelae SARS-CoV-2 infection symptoms. Ann Clin Transl Neurol 9:995&#x2013;1010. 10.1002/acn3.51578</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.51578</ArticleId><ArticleId IdType="pmc">PMC9268882</ArticleId><ArticleId IdType="pubmed">35702954</ArticleId></ArticleIdList></Reference><Reference><Citation>Hays RD, Spritzer KL, Schalet BD, Cella D (2018) PROMIS(&#xae;)-29 v2.0 profile physical and mental health summary scores. Qual Life Res Int J Qual Life Asp Treat Care Rehabil 27:1885&#x2013;1891. 10.1007/s11136-018-1842-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11136-018-1842-3</ArticleId><ArticleId IdType="pmc">PMC5999556</ArticleId><ArticleId IdType="pubmed">29569016</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiss DS (2007) The Impact of event scale: revised. In: Wilson JP, Tang CS (eds) Cross-cultural assessment of psychological trauma and PTSD Springer US, Boston, pp 219&#x2013;238</Citation></Reference><Reference><Citation>Asukai N, Kato H, Kawamura N et al. (2002) Reliability and validity of the Japanese-language version of the impact of event scale-revised (IES-R-J): four studies of different traumatic events. J Nerv Ment Dis 190:175&#x2013;182. 10.1097/00005053-200203000-00006</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005053-200203000-00006</ArticleId><ArticleId IdType="pubmed">11923652</ArticleId></ArticleIdList></Reference><Reference><Citation>Creamer M, Bell R, Failla S (2003) Psychometric properties of the impact of event scale-revised. Behav Res Ther 41:1489&#x2013;1496. 10.1016/j.brat.2003.07.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brat.2003.07.010</ArticleId><ArticleId IdType="pubmed">14705607</ArticleId></ArticleIdList></Reference><Reference><Citation>Larson RD (2013) Psychometric properties of the modified fatigue impact scale. Int J MS Care 15:15&#x2013;20. 10.7224/1537-2073.2012-019</Citation><ArticleIdList><ArticleId IdType="doi">10.7224/1537-2073.2012-019</ArticleId><ArticleId IdType="pmc">PMC3883028</ArticleId><ArticleId IdType="pubmed">24453758</ArticleId></ArticleIdList></Reference><Reference><Citation>Johns MW (1991) A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 14:540&#x2013;545. 10.1093/sleep/14.6.540</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/sleep/14.6.540</ArticleId><ArticleId IdType="pubmed">1798888</ArticleId></ArticleIdList></Reference><Reference><Citation>Nasreddine ZS, Phillips NA, B&#xe9;dirian V et al. (2005) The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 53:695&#x2013;699. 10.1111/j.1532-5415.2005.53221.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1532-5415.2005.53221.x</ArticleId><ArticleId IdType="pubmed">15817019</ArticleId></ArticleIdList></Reference><Reference><Citation>Flachenecker P, K&#xfc;mpfel T, Kallmann B et al. (2002) Fatigue in multiple sclerosis: a comparison of different rating scales and correlation to clinical parameters. Mult Scler Houndmills Basingstoke Engl 8:523&#x2013;526. 10.1191/1352458502ms839oa</Citation><ArticleIdList><ArticleId IdType="doi">10.1191/1352458502ms839oa</ArticleId><ArticleId IdType="pubmed">12474995</ArticleId></ArticleIdList></Reference><Reference><Citation>Sin DD (2023) Is long COVID an autoimmune disease? Eur Respir J 61:2202272. 10.1183/13993003.02272-2022</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.02272-2022</ArticleId><ArticleId IdType="pubmed">36634924</ArticleId></ArticleIdList></Reference><Reference><Citation>Braley TJ, Chervin RD (2010) Fatigue in multiple sclerosis: mechanisms, evaluation, and treatment. Sleep 33:1061&#x2013;1067. 10.1093/sleep/33.8.1061</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/sleep/33.8.1061</ArticleId><ArticleId IdType="pmc">PMC2910465</ArticleId><ArticleId IdType="pubmed">20815187</ArticleId></ArticleIdList></Reference><Reference><Citation>Azzolino D, Cesari M (2022) Fatigue in the COVID-19 pandemic. Lancet Healthy Longev 3:e128&#x2013;e129. 10.1016/S2666-7568(22)00029-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2666-7568(22)00029-0</ArticleId><ArticleId IdType="pmc">PMC8901180</ArticleId><ArticleId IdType="pubmed">35282597</ArticleId></ArticleIdList></Reference><Reference><Citation>Melamed I (2021) Study to Evaluate the Benefit of RUCONEST in Improving Neurological Symptoms in Post COVID-19 Infection
In: Clin. Identifier NCT04705831. https://clinicaltrials.gov/ct2/show/NCT04705831?term=neurologic&amp;type=Intr&amp;cond=COVID-19&amp;draw=2&amp;rank=7. Accessed
28 Sept 2022</Citation></Reference><Reference><Citation>Nacul L (2022) Low-dose Naltrexone for Post-COVID Fatigue Syndrome
In: Clin. Identifier NCT05430152. https://clinicaltrials.gov/ct2/show/NCT05430152. Accessed
28 Sept 2022</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11097836</ArticleId><ArticleId IdType="pubmed">38740499</ArticleId></ArticleIdList></Reference><Reference><Citation>Urwyler P, Moser S, Charitos P et al. (2020) Treatment of COVID-19 with conestat alfa, a regulator of the complement, contact activation and Kallikrein-Kinin System. Front Immunol 11:2072. 10.3389/fimmu.2020.02072</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.02072</ArticleId><ArticleId IdType="pmc">PMC7456998</ArticleId><ArticleId IdType="pubmed">32922409</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Z, You Y, Griffin N et al. (2018) Low-dose naltrexone (LDN): a promising treatment in immune-related diseases and cancer therapy. Int Immunopharmacol 61:178&#x2013;184. 10.1016/j.intimp.2018.05.020</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2018.05.020</ArticleId><ArticleId IdType="pubmed">29885638</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Kelly B, Vidal L, McHugh T et al. (2022) Safety and efficacy of low dose naltrexone in a long covid cohort; an interventional pre-post study. Brain Behav Immun Health 24:100485. 10.1016/j.bbih.2022.100485</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbih.2022.100485</ArticleId><ArticleId IdType="pmc">PMC9250701</ArticleId><ArticleId IdType="pubmed">35814187</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson JC, Lassen-Greene C, Jutte JE, Stepanovic K (2020) PTSD after critical illness: current issues and future directions. In: Preiser J-C, Herridge M, Azoulay E (eds) Post-intensive care syndrome Springer International Publishing, Cham, pp 177&#x2013;188</Citation></Reference><Reference><Citation>Ortona E, Malorni W (2022) Long COVID: to investigate immunological mechanisms and sex/gender related aspects as fundamental steps for tailored therapy. Eur Respir J 10.1183/13993003.02245-2021</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.02245-2021</ArticleId><ArticleId IdType="pmc">PMC8462012</ArticleId><ArticleId IdType="pubmed">34531277</ArticleId></ArticleIdList></Reference><Reference><Citation>Castanares-Zapatero D, Chalon P, Kohn L et al. (2022) Pathophysiology and mechanism of long COVID: a comprehensive review. Ann Med 54:1473&#x2013;1487. 10.1080/07853890.2022.2076901</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/07853890.2022.2076901</ArticleId><ArticleId IdType="pmc">PMC9132392</ArticleId><ArticleId IdType="pubmed">35594336</ArticleId></ArticleIdList></Reference><Reference><Citation>Nath A (2022) Immunotherapy for Neurological Post-Acute Sequelae of SARS-CoV-2
In: Clin. Identifier NCT05350774. https://clinicaltrials.gov/ct2/show/NCT05350774. Accessed
28 Sept 2022</Citation></Reference><Reference><Citation>Leppert D (2022) Temelimab as a Disease Modifying Therapy in PatientsWith Neuropsychiatric Symptoms in Post-COVID 19 or PASC Syndrome
In: Clin. Identifier NCT05497089. https://clinicaltrials.gov/ct2/show/NCT05497089?term=neurologic&amp;type=Intr&amp;cond=COVID-19&amp;draw=3&amp;rank=13. Accessed
28 Sept 2022</Citation></Reference><Reference><Citation>Kitsou K, Kotanidou A, Paraskevis D et al. (2021) Upregulation of human endogenous retroviruses in bronchoalveolar lavage fluid of COVID-19 patients. Microbiol Spectr 9:e0126021. 10.1128/Spectrum.01260-21</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/Spectrum.01260-21</ArticleId><ArticleId IdType="pmc">PMC8510252</ArticleId><ArticleId IdType="pubmed">34612698</ArticleId></ArticleIdList></Reference><Reference><Citation>Proal AD, VanElzakker MB (2021) Long COVID or post-acute sequelae of COVID-19 (PASC): an overview of biological factors that may contribute to persistent symptoms. Front Microbiol 12:698169. 10.3389/fmicb.2021.698169</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2021.698169</ArticleId><ArticleId IdType="pmc">PMC8260991</ArticleId><ArticleId IdType="pubmed">34248921</ArticleId></ArticleIdList></Reference><Reference><Citation>Curtin F, Bernard C, Levet S et al. (2018) A new therapeutic approach for type 1 diabetes: rationale for GNbAC1, an anti-HERV-W-Env monoclonal antibody. Diabetes Obes Metab 20:2075&#x2013;2084. 10.1111/dom.13357</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/dom.13357</ArticleId><ArticleId IdType="pubmed">29749030</ArticleId></ArticleIdList></Reference><Reference><Citation>Dolei A (2018) The aliens inside us: HERV-W endogenous retroviruses and multiple sclerosis. Mult Scler Houndmills Basingstoke Engl 24:42&#x2013;47. 10.1177/1352458517737370</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1352458517737370</ArticleId><ArticleId IdType="pubmed">29307292</ArticleId></ArticleIdList></Reference><Reference><Citation>Mameli G, Poddighe L, Mei A et al. (2012) Expression and activation by Epstein Barr virus of human endogenous retroviruses-W in blood cells and astrocytes: inference for multiple sclerosis. PLoS ONE 7:e44991. 10.1371/journal.pone.0044991</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0044991</ArticleId><ArticleId IdType="pmc">PMC3459916</ArticleId><ArticleId IdType="pubmed">23028727</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartung H-P, Derfuss T, Cree BA et al. (2022) Efficacy and safety of temelimab in multiple sclerosis: results of a randomized phase 2b and extension study. Mult Scler Houndmills Basingstoke Engl 28:429&#x2013;440. 10.1177/13524585211024997</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/13524585211024997</ArticleId><ArticleId IdType="pubmed">34240656</ArticleId></ArticleIdList></Reference><Reference><Citation>McIntyre RS (2022) Vortioxetine for Post-COVID-19 Condition
In: Clin. Identifier NCT05047952. https://clinicaltrials.gov/ct2/show/NCT05047952. Accessed
28 Sep 2022</Citation></Reference><Reference><Citation>Sanchez C, Asin KE, Artigas F (2015) Vortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical data. Pharmacol Ther 145:43&#x2013;57. 10.1016/j.pharmthera.2014.07.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pharmthera.2014.07.001</ArticleId><ArticleId IdType="pubmed">25016186</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreno-Torres I, Meca Lallana V, Costa-Frossard L et al. (2021) Risk and outcomes of COVID-19 in patients with multiple sclerosis. Eur J Neurol 28:3712&#x2013;3721. 10.1111/ene.14990</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.14990</ArticleId><ArticleId IdType="pmc">PMC8444942</ArticleId><ArticleId IdType="pubmed">34152073</ArticleId></ArticleIdList></Reference><Reference><Citation>Rass V, Beer R, Schiefecker AJ et al. (2022) Neurological outcomes 1 year after COVID-19 diagnosis: a prospective longitudinal cohort study. Eur J Neurol 29:1685&#x2013;1696. 10.1111/ene.15307</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.15307</ArticleId><ArticleId IdType="pmc">PMC9111823</ArticleId><ArticleId IdType="pubmed">35239247</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>